https://www.onclive.com/view/al-sawaf-highlights-the-benefit-of-fixed-duration-venetoclax-obinutuzumab-in-cll
Al-Sawaf Highlights the Benefit of Fixed-Duration Venetoclax/Obinutuzumab in CLL | OncLive
Oct 13, 2026 - Othman Al-Sawaf, MD, discusses the data from the CLL14 trial with obinutuzumab/venetoclax and the benefits of a fixed-dose treatment in select patients with...
the benefitsawafhighlightsfixedduration